# BENDEKA (bendamustine) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/bendamustine

> The FDA approved BENDEKA (bendamustine), sponsored by PFIZER INC (PFE), on December 15, 2022.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | BENDEKA (bendamustine) |
| Codes |  |
| Sponsor | PFIZER INC (PFE) https://sec-api.dev/companies/pfe/catalysts |
| Indications |  |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### December 15, 2022: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:48:32.313Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA211530 ORIG-1 (Type 5 - New Formulation or New Manufacturer): submission_status AP, submission_status_date 20221215, review_priority STANDARD; sponsor_name HOSPIRA; product BENDAMUSTINE HYDROCHLORIDE (BENDAMUSTINE HYDROCHLORIDE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA211530%22
- openFDA Drugs@FDA: "NDA216078 ORIG-1 (Type 5 - New Formulation or New Manufacturer): submission_status AP, submission_status_date 20221215, review_priority STANDARD; sponsor_name BAXTER HLTHCARE CORP; product BENDAMUSTINE HYDROCHLORIDE (BENDAMUSTINE HYDROCHLORIDE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA216078%22

### September 18, 2025: NDA/BLA submission

- Status: completed. Date confidence: exact.
- First seen 2026-09-03, last confirmed 2026-09-03.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-381899): "Similarly, on September 18, 2025, Teva and Eagle filed suit against Almaject, Inc. and Alvogen, Inc. in the District of Delaware following the filing of another 505(b)(2) NDA for a generic BENDEKA product." https://www.sec.gov/Archives/edgar/data/818686/000119312526381899/d153033dex991.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/bendamustine.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "BENDEKA (bendamustine) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/bendamustine

```bibtex
@misc{secapidev_pdufa_bendamustine_20261116,
  title        = {BENDEKA (bendamustine) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/bendamustine}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_bendamustine_20261116","title":"BENDEKA (bendamustine) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/bendamustine","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
